PHAT
Phathom Pharmaceuticals Inc
6.90$
-2.3%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 95.7% | 96.0% | 95.5% | 95.4% | 96.6% | 95.2% | 90.0% | 87.5% | 86.5% | 88.4% | 90.6% | 90.5% | |
| 90.2% | 92.2% | 90.4% | 86.5% | 86.5% | 78.6% | 72.2% | 59.8% | 56.2% | 50.2% | 59.3% | 55.8% | |
| 90.2% | 92.2% | 90.4% | 86.5% | 86.5% | 78.6% | 72.2% | 59.8% | 56.2% | 50.2% | 59.3% | 55.8% | |
| – | 0.4% | 1.1% | 3.4% | 5.4% | 10.3% | 12.4% | 20.5% | 23.2% | 30.1% | 26.5% | 29.8% | |
| 0.0% | 0.3% | 0.4% | 0.7% | 0.8% | 0.8% | 1.1% | 1.4% | 1.5% | 2.1% | 2.1% | 2.4% | |
| 107.5% | 117.6% | 141.7% | 173.2% | 148.3% | 167.0% | 215.0% | 262.2% | 275.8% | 269.1% | 210.4% | 205.3% | |
| 10.1% | 9.4% | 12.2% | 14.7% | 16.9% | 22.7% | 25.2% | 36.7% | 38.8% | 51.0% | 41.0% | 47.0% | |
| 0.3% | 0.2% | 0.2% | 0.2% | 0.2% | 0.1% | 0.1% | 0.1% | 0.2% | 0.3% | 0.2% | 0.2% | |
| 2.4% | 3.0% | 2.3% | 2.4% | 1.8% | 2.8% | 3.9% | 1.6% | 0.4% | 1.9% | 2.1% | 1.6% | |
| 41.9% | 33.3% | 41.8% | 54.6% | 45.4% | 53.2% | 69.1% | 82.0% | 86.2% | 80.7% | 53.6% | 50.3% | |
| -7.5% | -17.6% | -41.7% | -73.2% | -48.3% | -67.0% | -115.0% | -162.2% | -175.8% | -169.1% | -110.4% | -105.3% | |
| -358.3% | -224.4% | -283.7% | -345.4% | -307.1% | -333.8% | -461.3% | -572.8% | -608.9% | -572.7% | -496.4% | -468.5% | |
| 24.0% | 12.4% | 16.4% | 18.3% | 16.7% | 18.8% | 24.5% | 29.0% | 30.5% | 28.5% | 26.9% | 25.6% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.